Literature DB >> 32516741

Uncovering hidden pfhrp2/3 deletion Plasmodium falciparum.

Tamaki Kobayashi1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32516741      PMCID: PMC7281805          DOI: 10.1016/j.ebiom.2020.102781

Source DB:  PubMed          Journal:  EBioMedicine        ISSN: 2352-3964            Impact factor:   8.143


× No keyword cloud information.
Deaths and transmission from malaria have declined significantly in the past decade, although the progress has somewhat stalled in recent years [1]. Accurate and timely diagnosis is essential to providing adequate treatment to malaria cases. Plasmodium falciparum histidine-rich protein 2 (PfHRP2) based rapid diagnostic test (RDT) is widely used especially in Africa, where P. falciparum accounts for 98% of estimated malaria cases [1]. Despite its importance, reports of parasites lacking pfhrp2 gene emerging across the globe are threatening the importance of this malaria diagnostic tool. Peru is the first country that reported a high prevalence of pfhrp2 and pfhrp3 deleted strains in the field and warned that PfHRP2-based RDT should be replaced with a non-PfHRP2-based RDT or quality microscopic diagnosis [2]. The threat of false-negative PfHRP2-based RDT alarmed the World Health Organization (WHO) and recommendation for accurate reporting was updated in 2014 [3], followed by multiple reports by WHO Global malaria program [4]. In the African continent, where the burden of malaria mortality and morbidity are the highest, a recent review showed that the level of pfhrp2/3 gene deletion varied among 12 countries where pfhrp2/3 deletions were tested in Africa – the highest being Eritrea (62%), and the lowest being Angola (0.4%), with a caveat that sample collection and assay varied across studies [5]. Standardized surveillance protocol is now developed by WHO to study pfhrp2/3 deletion in malaria-endemic countries [6]. Based on the protocol, suspected PfHRP2-RDT false negative individuals, who are febrile, should be screened by microscopy or a pf-pLDH RDT [6]. Being negative with PfHRP2-based RDT, but positive with other screening methods indicate potential deletion, and if suspected deletion exceeds 5%, WHO urges to switch to non-PfHRP2-based RDTs or microscopy [6]. Although molecular confirmation of pfhrp2/3 deletion is currently not required, detecting the emergence of pfhrp2/3 deletion parasite and monitoring it can assist malaria-endemic countries to make a plan accordingly. When screening for deletion, infection with multiple clones of parasites can cause difficulty to analyze the results, since the presence of pfhrp2/3 deletion parasite can be masked by the presence of pfhrp2/3 un-deleted parasites. In an article in EBioMedicine, Grignard and colleagues [7] propose a novel multiplex qPCR assay that addresses the issue of polyclonal infection. The authors went through meticulous optimization and validation process. In the final multiplex qPCR assay, host DNA (human beta tubulin (HumTuBB)), a single-copy parasite house-keeping gene (P. falciparum lactate dehydrogenase (pfldh)), as well as pfhrp2 and pfhrp3 are simultaneously detected using specific primers and probes. They used pfldh to confirm the presence as well as quantification of parasite DNA, and used HumTuBB to normalize relative parasite densities in each sample. Using the developed and validated assay, the authors tested various field samples including; dried blood spots (DBS) from Eritrea (n = 50), whole blood collected from symptomatic individuals in Kenya (n = 150) and Tanzania (n = 149), and confirmed P. falciparum in whole blood samples collected from UK travelers (n = 113) at Public Health England Malaria Reference Library. Of those tested, 31 (62%), 0 (0%), 1 (0.7%), and 1 (3.5%) were pfhrp2/3 double deletions among samples from Eritrea, Kenya, Tanzania and UK travelers, respectively. Furthermore, when polyclonal infections were taken into account, the authors reported additional pfhrp2, pfhrp3 or pfhrp2/3 deletions among samples from Kenya, and UK travelers. The current UK recommendation for malaria diagnosis is a thick and thin smear, but when a microscopist is inexperienced or unavailable, RDT plays a back-up diagnostic role. Given the caveats reported in this paper, the authors recommend that PfHRP2-based RDT results should be interpreted cautiously if that is used when microscopy analysis is not available. The use of pfldh quantification as normalizer without the human gene was previously reported [8]. Grignard and colleagues report that they have tried both methods (delta Ct vs delta delta Ct) and are comparable while adding a complex layer of internal control measure [7]. As it is commonly known that field samples can be collected and prepared in various ways. DBS is one of the sources of DNA the authors used in this manuscript and this could potentially contribute to a sample quality bias – partially filled or oversaturated. Incorporating an additional layer of normalization to the analysis is one of the ways to ensure the results are comparable across time and location. Detecting pfhrp2/3 deletion parasites masked by polyclonal infection may not change the result of the diagnosis, however, detecting the emergence and monitoring its spread over the course of time will enable countries and communities affected by malaria plan for the change in malaria diagnostic tools before the surge of parasite strains that are undetectable by current PfHRP2-based RDTs.

Declaration of Competing Interest

Dr. Kobayashi has nothing to disclose.
  5 in total

1.  A large proportion of P. falciparum isolates in the Amazon region of Peru lack pfhrp2 and pfhrp3: implications for malaria rapid diagnostic tests.

Authors:  Dionicia Gamboa; Mei-Fong Ho; Jorge Bendezu; Katherine Torres; Peter L Chiodini; John W Barnwell; Sandra Incardona; Mark Perkins; David Bell; James McCarthy; Qin Cheng
Journal:  PLoS One       Date:  2010-01-25       Impact factor: 3.240

2.  A multiplex qPCR approach for detection of pfhrp2 and pfhrp3 gene deletions in multiple strain infections of Plasmodium falciparum.

Authors:  Tobias Schindler; Anna C Deal; Martina Fink; Etienne Guirou; Kara A Moser; Solomon M Mwakasungula; Michael G Mihayo; Said A Jongo; Prosper P Chaki; Salim Abdulla; Paulo C Manrique Valverde; Katherine Torres; Jose R Bijeri; Joana C Silva; Stephen L Hoffman; Dionicia Gamboa; Marcel Tanner; Claudia Daubenberger
Journal:  Sci Rep       Date:  2019-09-11       Impact factor: 4.379

3.  A novel multiplex qPCR assay for detection of Plasmodium falciparum with histidine-rich protein 2 and 3 (pfhrp2 and pfhrp3) deletions in polyclonal infections.

Authors:  Lynn Grignard; Debbie Nolder; Nuno Sepúlveda; Araia Berhane; Selam Mihreteab; Robert Kaaya; Jody Phelan; Kara Moser; Donelly A van Schalkwyk; Susana Campino; Jonathan B Parr; Jonathan J Juliano; Peter Chiodini; Jane Cunningham; Colin J Sutherland; Chris Drakeley; Khalid B Beshir
Journal:  EBioMedicine       Date:  2020-05-08       Impact factor: 8.143

4.  Systematic review of the status of pfhrp2 and pfhrp3 gene deletion, approaches and methods used for its estimation and reporting in Plasmodium falciparum populations in Africa: review of published studies 2010-2019.

Authors:  Bosco B Agaba; Adoke Yeka; Sam Nsobya; Emmanuel Arinaitwe; Joaniter Nankabirwa; Jimmy Opigo; Paul Mbaka; Chae Seung Lim; Joan N Kalyango; Charles Karamagi; Moses R Kamya
Journal:  Malar J       Date:  2019-11-06       Impact factor: 2.979

Review 5.  Plasmodium falciparum parasites lacking histidine-rich protein 2 and 3: a review and recommendations for accurate reporting.

Authors:  Qin Cheng; Michelle L Gatton; John Barnwell; Peter Chiodini; James McCarthy; David Bell; Jane Cunningham
Journal:  Malar J       Date:  2014-07-22       Impact factor: 2.979

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.